Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

PR Newswire - Fri Jun 2, 2023

SAN DIEGO, June 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA^® (valbenazine) capsules that demonstrated substantial and sustained improvements in tardive dyskinesia (TD) in adults with or without concomitant antipsychotic therapy. The data (Poster #4) were presented at 2023 Psych Congress Elevate in Las Vegas.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market

Dividend investing has lost its mojo. Here’s why – and how to adapt

inside the market

The Globe Investing Club 2024: Let the competition begin!

Here’s the real reason your Canadian stocks can’t keep up

Dow ends above 40,000 milestone, TSX also at fresh record high

number cruncher

U.S technology stocks with earnings and price momentum

report on business

Lightspeed Commerce stock soars on better-than-expected profit forecast

GameStop, AMC dive further as meme stocks rally tapers off

The close: Dow briefly hits 40,000 milestone, TSX rises on upbeat earnings